D C Morris1, Y Cui2, W L Cheung3, M Lu4, L Zhang5, Z G Zhang6, M Chopp7. 1. Department of Emergency Medicine, Henry Ford Health Systems, Detroit, MI 48202, USA. Electronic address: morris@neuro.hfh.edu. 2. Department of Neurology, Henry Ford Health Systems, Detroit, MI 48202, USA. Electronic address: yisheng@neuro.hfh.edu. 3. Department of Emergency Medicine, Henry Ford Health Systems, Detroit, MI 48202, USA. Electronic address: wcheung1@hfhs.org. 4. Department of Public Health Sciences, Henry Ford Health Systems, Detroit, MI 48202, USA. Electronic address: mlu1@hfhs.org. 5. Department of Neurology, Henry Ford Health Systems, Detroit, MI 48202, USA. Electronic address: lzhang@neuro.hfh.edu. 6. Department of Neurology, Henry Ford Health Systems, Detroit, MI 48202, USA. Electronic address: zhazh@neuro.hfh.edu. 7. Department of Neurology, Henry Ford Health Systems, Detroit, MI 48202, USA; Department of Physics, Oakland University, Rochester, MI 48309, USA. Electronic address: michael.chopp@gmail.com.
Abstract
BACKGROUND: Thymosin β4 (Tβ4) is a 5K actin binding peptide. Tβ4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this study was to perform a dose-response study of Tβ4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. METHODS: Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg. Tβ4 was administered intraperitoneally 24h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized estimating equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. RESULTS: Tβ4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values <0.05). The higher dose of 18 mg/kg did not show significant improvement. The estimated optimal dose of 3.75 mg/kg would provide optimal neurological improvement. CONCLUSIONS: This study shown that Tβ4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials.
BACKGROUND: Thymosin β4 (Tβ4) is a 5K actin binding peptide. Tβ4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this study was to perform a dose-response study of Tβ4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. METHODS: Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg. Tβ4 was administered intraperitoneally 24h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized estimating equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. RESULTS: Tβ4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values <0.05). The higher dose of 18 mg/kg did not show significant improvement. The estimated optimal dose of 3.75 mg/kg would provide optimal neurological improvement. CONCLUSIONS: This study shown that Tβ4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials.
Authors: K M Malinda; G S Sidhu; H Mani; K Banaudha; R K Maheshwari; A L Goldstein; H K Kleinman Journal: J Invest Dermatol Date: 1999-09 Impact factor: 8.551
Authors: Li Zhang; Michael Chopp; Rui Lan Zhang; Lei Wang; Jing Zhang; Ying Wang; Yier Toh; Manoranjan Santra; Mei Lu; Zheng Gang Zhang Journal: PLoS One Date: 2010-06-11 Impact factor: 3.240
Authors: William J Mason; Daniyal J Jafree; Gideon Pomeranz; Maria Kolatsi-Joannou; Antje K Rottner; Sabrina Pacheco; Dale A Moulding; Anja Wolf; Christian Kupatt; Claire Peppiatt-Wildman; Eugenia Papakrivopoulou; Paul R Riley; David A Long; Elisavet Vasilopoulou Journal: Sci Rep Date: 2022-07-16 Impact factor: 4.996
Authors: Daniel C Morris; Wing Lee Cheung; Richard Loi; Talan Zhang; Mei Lu; Zheng G Zhang; Michael Chopp Journal: Neurosci Lett Date: 2017-08-31 Impact factor: 3.046
Authors: Christoffer K-J Stark; Miikka Tarkia; Rasmus Kentala; Markus Malmberg; Tommi Vähäsilta; Matti Savo; Ville-Veikko Hynninen; Mikko Helenius; Saku Ruohonen; Juho Jalkanen; Pekka Taimen; Tero-Pekka Alastalo; Antti Saraste; Juhani Knuuti; Timo Savunen; Juha Koskenvuo Journal: Front Pharmacol Date: 2016-05-03 Impact factor: 5.810
Authors: Elisavet Vasilopoulou; Maria Kolatsi-Joannou; Maja T Lindenmeyer; Kathryn E White; Michael G Robson; Clemens D Cohen; Neil J Sebire; Paul R Riley; Paul J Winyard; David A Long Journal: Kidney Int Date: 2016-08-26 Impact factor: 10.612